Clarithromycin's improved acid stability and superior tissue distribution relative to erythromycin have made it a preferred advanced-generation macrolide in companion animal practice, especially for resistant upper respiratory and dermatological infections. Its immunomodulatory properties also support off-label use in chronic inflammatory airway disease in dogs and cats.
Quick Facts
| CAS Number | 81103-11-9 |
|---|---|
| Molecular Formula | C38H69NO13 |
| Molecular Weight | 748 |
| Pharmacopoeia | EP/USP/IP/CP |
| Packaging | 25 KG/DRUM |
Product Overview
Clarithromycin is an advanced macrolide antibiotic for veterinary use, derived from erythromycin with improved acid stability and oral bioavailability. Its 14-hydroxy metabolite is also microbiologically active, enhancing its effectiveness against a wider range of pathogens.
Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It demonstrates efficacy against respiratory pathogens, Helicobacter species, and Mycobacteria. Primarily used in companion animal medicine and specialized livestock applications requiring advanced macrolide therapy.
Quality Specifications
| Purity | As per USP monograph |
|---|---|
| Residual Solvents | Compliant with ICH Q3C |
| Heavy Metals | Compliant with pharmacopoeia limits |
| GMP Status | Manufactured under GMP conditions |
Veterinary Applications
- Companion animal respiratory infections: Treatment of upper and lower respiratory tract infections in dogs and cats
- Canine Helicobacter gastritis: Management of gastric Helicobacter infections
- Feline mycobacterial infections: Treatment of atypical mycobacteriosis in cats
- Specialized poultry applications: Targeted use for specific bacterial pathogens
- Exotic animal medicine: Respiratory and mycobacterial infections in exotic and zoo animals